Neuroregeneration

Pipeline Therapeutics to Present at Three Upcoming Investor Conferences

Retrieved on: 
Tuesday, July 28, 2020
Biotechnology, Pharmaceutical, Health, Neurology, Remyelination, Neuroregeneration, Axon, Biology

Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced the company will participate in three upcoming investor conferences in August.

Key Points: 
  • Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced the company will participate in three upcoming investor conferences in August.
  • Pipeline Therapeutics is a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, including synaptogenesis, remyelination and axonal repair.
  • The company's lead clinical program, PIPE-505, is currently enrolling patients in a phase 1/2a study to treat mild-to-moderate sensorineural hearing loss (SNHL) associated with speech-in-noise disability.
  • The company also has a portfolio of programs addressing a range of neurological disorders, including development candidate PIPE-307 which is focused on remyelination to treat multiple sclerosis.

Axogen, Inc. to Report Second Quarter 2020 Financial Results and Host Conference Call on August 5, 2020

Retrieved on: 
Wednesday, July 15, 2020
Branches of biology, Nervous system, Organ systems, Neurophysiology, AxoGen, Neuroregeneration, Nerve, Peripheral nervous system

ALACHUA, Fla., July 15, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today confirmed that it will report second quarter 2020 financial results on Wednesday, August 5, 2020 after the market closes.

Key Points: 
  • ALACHUA, Fla., July 15, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today confirmed that it will report second quarter 2020 financial results on Wednesday, August 5, 2020 after the market closes.
  • Axogen management will host an investment-community conference call and webcast following the release at 4:30 p.m.
  • Axogen (AXGN) is the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair.
  • The Axogen portfolio of products is available in the United States, Canada, the United Kingdom, South Korea, and several other European and international countries.

Worldwide Nerve Repair and Regeneration Market to 2025 - Featuring Abbott Laboratories, Baxter & Medtronic Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 30, 2020
Health, Biotechnology, Articles, Health, Branches of biology, Neurophysiology, Global health, Health informatics, Neuroregeneration, Dementia, Nerve, Disease burden, Forecasting

The "Nerve Repair and Regeneration Market - Growth, Trends, and Forecasts (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Nerve Repair and Regeneration Market - Growth, Trends, and Forecasts (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.
  • The Nerve Repair and Regeneration Market are expected to register a CAGR of 12.2% during the forecast period.
  • The increase in neurological diseases is found to be the major contributors to the global burden of disease.
  • As a number of people will dementia is expected to double in the near future which is expected to boost the market.

Pipeline Therapeutics to Present at the Jefferies Virtual Global Healthcare Conference

Retrieved on: 
Thursday, May 28, 2020
Biotechnology, General Health, Pharmaceutical, Health, Branches of biology, Organ systems, Neurophysiology, Neuroregeneration, Nervous system, Axon, Synaptopathy, Sensorineural hearing loss

Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced that Carmine Stengone, President and Chief Executive Officer, will present at the Jefferies Virtual Global Healthcare Conference on Thu, Jun 4, 2020 at 3:00 p.m.

Key Points: 
  • Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced that Carmine Stengone, President and Chief Executive Officer, will present at the Jefferies Virtual Global Healthcare Conference on Thu, Jun 4, 2020 at 3:00 p.m.
  • Pipeline Therapeutics is a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, including synaptogenesis, remyelination and axonal repair.
  • The companys lead product candidate, PIPE-505, is a small molecule gamma secretase inhibitor (GSI) to treat mild-to-moderate sensorineural hearing loss (SNHL) associated with cochlear synaptopathy.
  • The company also has a portfolio of programs, including PIPE-307, focused on remyelination and axonal repair, to address a range of neurological disorders, including multiple sclerosis.

Axogen, Inc. to Present at the Jefferies Virtual Healthcare Conference

Retrieved on: 
Wednesday, May 20, 2020
Nervous system, Organ systems, Branches of biology, Neurophysiology, Neuroregeneration, AxoGen, Nerve

ALACHUA, Fla., May 20, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president will present at the Jefferies Virtual Healthcare Conference.

Key Points: 
  • ALACHUA, Fla., May 20, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president will present at the Jefferies Virtual Healthcare Conference.
  • The presentation will be webcast live and can be accessed through the Investors page at www.axogeninc.com .
  • Axogen (AXGN) is the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair.
  • The Axogen portfolio of products is available in the United States, Canada, the United Kingdom, South Korea, and several other European and international countries.

United States Soft Tissue Repair Markets 2020-2026: Breast Reconstruction, Hernia Repair, Dural Repair, Dental Soft Tissue Regeneration, Nerve Repair, and Cardiovascular Repair Markets

Retrieved on: 
Wednesday, May 6, 2020
Medicine, Clinical medicine, Medical specialties, Digestive system surgery, Hernias, Hernia repair, Neuroregeneration

DUBLIN, May 6, 2020 /PRNewswire/ -- The "Soft Tissue Repair Market Analysis | United States | 2020-2026 | MedSuite" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, May 6, 2020 /PRNewswire/ -- The "Soft Tissue Repair Market Analysis | United States | 2020-2026 | MedSuite" report has been added to ResearchAndMarkets.com's offering.
  • In 2019, the U.S. market for soft tissue repair is expected to grow at a high-single-digit rate over the forecast period.
  • This is mainly driven by increases in unit sales, as medical conditions become more prevalent and/or procedures become more common.
  • This report on the U.S. market for soft tissue repair includes breast reconstruction, hernia repair, dural repair, dental soft tissue regeneration, nerve repair and cardiovascular repair.

Soft Tissue Repair Market Analysis | United States | 2020-2026 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 6, 2020
Health, Other Health, Medicine, Clinical medicine, Medical specialties, Digestive system surgery, Hernias, Hernia repair, Neuroregeneration, Tissue engineering

The "Soft Tissue Repair Market Analysis | United States | 2020-2026 | MedSuite" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Soft Tissue Repair Market Analysis | United States | 2020-2026 | MedSuite" report has been added to ResearchAndMarkets.com's offering.
  • In 2019, the U.S. market for soft tissue repair is expected to grow at a high-single-digit rate over the forecast period.
  • This is mainly driven by increases in unit sales, as medical conditions become more prevalent and/or procedures become more common.
  • This report on the U.S. market for soft tissue repair includes breast reconstruction, hernia repair, dural repair, dental soft tissue regeneration, nerve repair and cardiovascular repair.

Nerve Repair and Regeneration Market Report 2020: Global Trends, Forecast and Competitive Analysis (2013-2024) - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 14, 2020
Surgery, Health, Medical devices, Branches of biology, Organ systems, Nervous system, Neurophysiology, Neuroregeneration, Nerve, Regeneration

The "Nerve Repair and Regeneration Market Report: Trends, Forecast, and Competitive Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Nerve Repair and Regeneration Market Report: Trends, Forecast, and Competitive Analysis" report has been added to ResearchAndMarkets.com's offering.
  • The study includes the nerve repair and regeneration market size and forecast for the global nerve repair and regeneration market through 2024, segmented by product, application, end users, and region.
  • Growth opportunities: Analysis on growth opportunities in different applications and regions for nerve repair and regeneration in the global nerve repair and regeneration market.
  • Strategic analysis: This includes M&A, new product development, and competitive landscape for, nerve repair and regeneration in the global nerve repair and regeneration market.

Nerve Repair and Regeneration Markets, 2020-2024 Featuring Profiles of Axogen, Baxter, Boston Scientific, Livanova, Integra Lifesciences, Medtronic, Abbott Laboratories, Stryker, and More

Retrieved on: 
Thursday, April 9, 2020
Branches of biology, Organ systems, Nervous system, Neurophysiology, Neuroregeneration, Nerve, Regeneration, Nerve injury

The global nerve repair and regeneration market is expected to grow with a CAGR of 13% from 2019 to 2024.

Key Points: 
  • The global nerve repair and regeneration market is expected to grow with a CAGR of 13% from 2019 to 2024.
  • The study includes the nerve repair and regeneration market size and forecast for the global nerve repair and regeneration market through 2024, segmented by product, application, end users, and region.
  • Growth opportunities: Analysis on growth opportunities in different applications and regions for nerve repair and regeneration in the global nerve repair and regeneration market.
  • Strategic analysis: This includes M&A, new product development, and competitive landscape for, nerve repair and regeneration in the global nerve repair and regeneration market.

Pipeline Therapeutics to Participate in the 19th Annual Needham Virtual Healthcare Conference

Retrieved on: 
Thursday, April 9, 2020
Biotechnology, Pharmaceutical, Health, Neurophysiology, Neuroregeneration, Axon, Synaptopathy, Biology

Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced that the company will participate in the 19th Annual Needham Virtual Healthcare Conference, a fully virtual management access conference, taking place April 14-15.

Key Points: 
  • Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced that the company will participate in the 19th Annual Needham Virtual Healthcare Conference, a fully virtual management access conference, taking place April 14-15.
  • Pipeline Therapeutics is a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, including synaptogenesis, remyelination and axonal repair.
  • The companys lead product candidate, PIPE-505, is a small molecule gamma secretase inhibitor (GSI) to treat mild-to-moderate sensorineural hearing loss (SNHL) associated with cochlear synaptopathy.
  • The company also has a portfolio of programs, including PIPE-307, focused on remyelination and axonal repair, to address a range of neurological disorders, including multiple sclerosis.